Please assess the completion status of the following clinical trial:

Trial Title: Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 19+~2. Patients treated with a new generation of Evelorimus-eluting stents (Synergy®)~3. Patients who understand the content of the subject description and voluntarily sign the subject~Exclusion Criteria:~1. Age 86+~2. Hemodynamically unstable patient~3. Severe hypersensitivity reactions to aspirin, clopidogrel, ticagrelor, everolimus, contrast agent~4. Patients at high risk of bleeding, anemia, thrombocytopenia~5. Patients requiring oral anticoagulants~6. Pregnant women or women of childbearing age~7. Life expectancy is less than one year~8. Patients receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin, napjodone, ritonavir, atazanavir)~9. Patients with a history of intracranial hemorrhage~10. Patients with moderate to severe hepatic impairment~11. Patients underwent coronary intervention with stenting within 1 year~12. Patients with left-main lesions requiring coronary intervention~13. Patients with chronic stricture lesions requiring treatment~14. Patients with in-stent restenosis in a lesion requiring treatment~15. Patients with bifurcation lesions requiring stenting in lateral branches~16. Patients with lesions requiring more than 3 stents

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- P2Y12 antagonist monotherapy (Type: EXPERIMENTAL): P2Y12 antagonist monotherapy after 3-month DAPT
- Aspirin + P2Y12 antagonist (Type: ACTIVE_COMPARATOR): Aspirin + P2Y12 antagonist after 3-month DAPT

Based on this trial design, predict the completion outcome and termination type (if applicable).